Accession Number:

ADP013421

Title:

Stabilization of Pyridostigmine as Preventive Antidote

Descriptive Note:

Corporate Author:

ARMY CENTER FOR MEDICAL RESEARCH BUCHAREST (ROMANIA)

Report Date:

2001-09-01

Pagination or Media Count:

7.0

Abstract:

Pyridostigmine 3 hydroxy- 1 -methylpyridinium bromide dimethylcarbamate facilitates the transmission of impulses across the myoneural junction by inhibiting the destruction of acetylcholine by cholinesterase. In current therapy pyridostigmine tablets are useful in the treatment of myasthenia gravis being put on the market by Roche with the name Mestinon. In the form of manganese bromide salt, Arzneimittelwerk Dresden produced pyridostigmine with the name Kalymin 60. As a preventive antidote, pyridostigmine was produced by DuPhar. Design of oral antidotes based on pyridostigmine meet some scientific and logistic real challenges. The logistics challenge is common to almost all antidotes - scarce utilization in therapy, high cost and as a consequence, low interest it concerns its developing by the pharmaceutical companies.

Subject Categories:

  • Toxicology
  • Pharmacology
  • Chemical, Biological and Radiological Warfare

Distribution Statement:

APPROVED FOR PUBLIC RELEASE